Efinopegdutide — EU research guide.
Efinopegdutide (MK-6024) is Merck's investigational dual GLP-1/glucagon receptor agonist, developed primarily for metabolic liver disease (MASH) rather than weight loss alone.
What is Efinopegdutide?
By co-activating glucagon receptors alongside GLP-1, efinopegdutide is designed to burn hepatic fat directly, not just reduce appetite — a mechanism shared with survodutide and pemvidutide.
What does the research show?
In a Phase 2a NAFLD trial, once-weekly efinopegdutide cut liver fat by 72.7% over 24 weeks, versus 42.3% for semaglutide — a notably larger effect. Merck holds FDA Fast Track designation for NASH/MASH, with Phase 2b trials ongoing in precirrhotic MASH and compensated cirrhosis (2026).
EU legal status
Not approved anywhere. Efinopegdutide is an investigational pharmaceutical owned by Merck; it has no legitimate research-peptide supply route.
Molecular information
Pharmacokinetics
Dual-agonist compounds across EU suppliers
COA-verified EU vendors · Updated monthly